Literature DB >> 22811875

Ca19-9 and pancreatic cancer: Is it really that good?

Gareth Morris-Stiff1, Mark A Taylor.   

Abstract

Entities:  

Year:  2012        PMID： 22811875      PMCID： PMC3397655          DOI： 10.3978/j.issn.2078-6891.2012.016

Source DB:  PubMed          Journal:  J Gastrointest Oncol        ISSN： 2078-6891


× No keyword cloud information.
  9 in total

1.  The clinical utility and limitations of serum carbohydrate antigen (CA19-9) as a diagnostic tool for pancreatic cancer and cholangiocarcinoma.

Authors:  Sundeep Singh; Shou-jiang Tang; Jayaprakash Sreenarasimhaiah; Luis F Lara; Ali Siddiqui
Journal:  Dig Dis Sci       Date:  2011-04-23       Impact factor: 3.199

Review 2.  International consensus guidelines for management of intraductal papillary mucinous neoplasms and mucinous cystic neoplasms of the pancreas.

Authors:  Masao Tanaka; Suresh Chari; Volkan Adsay; Carlos Fernandez-del Castillo; Massimo Falconi; Michio Shimizu; Koji Yamaguchi; Kenji Yamao; Seiki Matsuno
Journal:  Pancreatology       Date:  2006       Impact factor: 3.996

Review 3.  Resection margins and R1 rates in pancreatic cancer--are we there yet?

Authors:  C S Verbeke
Journal:  Histopathology       Date:  2007-12-13       Impact factor: 5.087

4.  Redefining the R1 resection in pancreatic cancer.

Authors:  C S Verbeke; D Leitch; K V Menon; M J McMahon; P J Guillou; A Anthoney
Journal:  Br J Surg       Date:  2006-10       Impact factor: 6.939

5.  The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal.

Authors:  Umashankar K Ballehaninna; Ronald S Chamberlain
Journal:  J Gastrointest Oncol       Date:  2012-06

6.  ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer.

Authors:  Gershon Y Locker; Stanley Hamilton; Jules Harris; John M Jessup; Nancy Kemeny; John S Macdonald; Mark R Somerfield; Daniel F Hayes; Robert C Bast
Journal:  J Clin Oncol       Date:  2006-10-23       Impact factor: 44.544

7.  CA19-9 antigen levels can distinguish between benign and malignant pancreaticobiliary disease.

Authors:  Gareth Morris-Stiff; Mary Teli; Nicky Jardine; Malcolm Ca Puntis
Journal:  Hepatobiliary Pancreat Dis Int       Date:  2009-12

8.  CA19-9 serum levels in obstructive jaundice: clinical value in benign and malignant conditions.

Authors:  Daniele Marrelli; Stefano Caruso; Corrado Pedrazzani; Alessandro Neri; Eduardo Fernandes; Mario Marini; Enrico Pinto; Franco Roviello
Journal:  Am J Surg       Date:  2009-04-17       Impact factor: 2.565

9.  How do we interpret an elevated carbohydrate antigen 19-9 level in asymptomatic subjects?

Authors:  B J Kim; K T Lee; T G Moon; P Kang; J K Lee; J J Kim; J C Rhee
Journal:  Dig Liver Dis       Date:  2009-01-21       Impact factor: 4.088
  9 in total
  10 in total

1.  Detection of pancreatic cancer with normal carbohydrate antigen 19-9 using protein chip technology.

Authors:  Xiao-Li Jin; Bin Xu; Yu-Lian Wu
Journal:  World J Gastroenterol       Date:  2014-10-28       Impact factor: 5.742

2.  Mutant KRAS Circulating Tumor DNA Is an Accurate Tool for Pancreatic Cancer Monitoring.

Authors:  Ruth Perets; Orli Greenberg; Talia Shentzer; Valeria Semenisty; Ron Epelbaum; Tova Bick; Shada Sarji; Ofer Ben-Izhak; Edmond Sabo; Dov Hershkovitz
Journal:  Oncologist       Date:  2018-01-25

Review 3.  White paper on pancreatic ductal adenocarcinoma from society of abdominal radiology's disease-focused panel for pancreatic ductal adenocarcinoma: Part I, AJCC staging system, NCCN guidelines, and borderline resectable disease.

Authors:  Naveen M Kulkarni; Erik V Soloff; Parag P Tolat; Guillermo P Sangster; Jason B Fleming; Olga R Brook; Zhen Jane Wang; Elizabeth M Hecht; Marc Zins; Priya R Bhosale; Hina Arif-Tiwari; Lorenzo Mannelli; Avinash R Kambadakone; Eric P Tamm
Journal:  Abdom Radiol (NY)       Date:  2020-03

4.  Dynamic change of serum CA19-9 levels in benign and malignant patients with obstructive jaundice after biliary drainage and new correction formulas.

Authors:  Bangbo Zhao; Qin Cheng; Hongtao Cao; Xingtong Zhou; Tianhao Li; Liangbo Dong; Weibin Wang
Journal:  BMC Cancer       Date:  2021-05-07       Impact factor: 4.430

5.  MicroRNA markers for the diagnosis of pancreatic and biliary-tract cancers.

Authors:  Motohiro Kojima; Hiroko Sudo; Junpei Kawauchi; Satoko Takizawa; Satoshi Kondou; Hitoshi Nobumasa; Atsushi Ochiai
Journal:  PLoS One       Date:  2015-02-23       Impact factor: 3.240

6.  Consensus guidelines for diagnosis, treatment and follow-up of patients with pancreatic cancer in Spain.

Authors:  M Hidalgo; R Álvarez; J Gallego; C Guillén-Ponce; B Laquente; T Macarulla; A Muñoz; M Salgado; R Vera; J Adeva; I Alés; S Arévalo; J Blázquez; A Calsina; A Carmona; E de Madaria; R Díaz; L Díez; T Fernández; B G de Paredes; M E Gallardo; I González; O Hernando; P Jiménez; A López; C López; F López-Ríos; E Martín; J Martínez; A Martínez; J Montans; R Pazo; J C Plaza; I Peiró; J J Reina; A Sanjuanbenito; R Yaya; Alfredo Carrato
Journal:  Clin Transl Oncol       Date:  2016-12-19       Impact factor: 3.405

7.  Individualized metabolic profiling stratifies pancreatic and biliary tract cancer: a useful tool for innovative screening programs and predictive strategies in healthcare.

Authors:  Jun Hwa Lee; Seung Eun Yu; Kyung-Hee Kim; Myung Hyun Yu; In-Hye Jeong; Jae Youl Cho; Sang-Jae Park; Woo Jin Lee; Sung-Sik Han; Tae Hyun Kim; Eun Kyung Hong; Sang Myung Woo; Byong Chul Yoo
Journal:  EPMA J       Date:  2018-08-17       Impact factor: 6.543

8.  Usefulness of serum microRNA as a predictive marker of recurrence and prognosis in biliary tract cancer after radical surgery.

Authors:  Yu Akazawa; Shoichi Mizuno; Norihiro Fujinami; Toshihiro Suzuki; Yusuke Yoshioka; Takahiro Ochiya; Yasunari Nakamoto; Tetsuya Nakatsura
Journal:  Sci Rep       Date:  2019-04-11       Impact factor: 4.379

9.  Serum levels of IL-6 and CRP can predict the efficacy of mFOLFIRINOX in patients with advanced pancreatic cancer.

Authors:  Feifei Shen; Chuan Liu; Weiguo Zhang; Sijia He; Fan Wang; Jingjue Wang; Qi Li; Fei Zhou
Journal:  Front Oncol       Date:  2022-07-29       Impact factor: 5.738

Review 10.  Current Standards and Recent Advances in Biomarkers of Major Endocrine Tumors.

Authors:  Yanhong Luo; Hua Zhu; Tao Tan; Jianfeng He
Journal:  Front Pharmacol       Date:  2018-09-10       Impact factor: 5.810
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.